Drug Profile
Telaglenastat - Cornerstone Pharmaceuticals
Alternative Names: CB 839Latest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator Calithera Biosciences
- Developer Calithera Biosciences; Case Western Reserve University; Cornerstone Pharmaceuticals Inc; M. D. Anderson Cancer Center; National Cancer Institute (USA); Pfizer
- Class Acetamides; Antineoplastics; Ethers; Fluorinated hydrocarbons; Pyridazines; Pyridines; Small molecules; Thiadiazoles
- Mechanism of Action Glutaminase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Chronic obstructive pulmonary disease
- Discontinued Colorectal cancer; Glioma; Haematological malignancies; Leukaemia; Malignant melanoma; Multiple myeloma; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer
Most Recent Events
- 08 Mar 2024 National Cancer Institute reinitiates a phase I trial for non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT04250545)
- 11 Sep 2023 Preclinical trials in Cancer in USA (PO), prior to September 2023 (Cornerstone Pharmaceuticals, Inc pipeline, September 2023)
- 09 Sep 2023 Preclinical trials in Chronic obstructive pulmonary disease in USA (Intranasal) before September 2023